Zume
Search results
Zymergen was an American biotechnology company based in Emeryville, California. The company applies genomics and machine learning to research and design chemical producing genetically modified organisms. It claimed that its manufacturing process was safer and cheaper than traditional manufacturing, but was unable to demonstrate this.
Oct 19, 2022 · Ginkgo Bioworks, a company that designs and builds biological systems, announces its completed acquisition of Zymergen, a company that develops automation and software solutions for biological engineering. The acquisition is expected to enhance Ginkgo's platform and expand its product concepts and partnerships.
Jul 25, 2022 · Zymergen, a synthetic biology company that shifted to drug discovery in January, has been acquired by Ginkgo Bioworks for $300 million. Ginkgo plans to integrate Zymergen's automation and software into its cell engineering platform, while evaluating strategic alternatives for its drug discovery business.
- James Waldron
Oct 13, 2021 · Zymergen raised $500 million when it went public in April, on top of more than $1 billion in venture funding. By August, its CEO was out and the synthetic biology company wouldn’t say when it ...
Jul 25, 2022 · Ginkgo Bioworks acquired biotechnology firm Zymergen, the synthetic biology companies announced Monday morning, marking the final act in Zymergen’s dramatic and brisk fall from grace.
- Derek Saul
Oct 19, 2022 · Ginkgo Bioworks, a biotech company that programs cells, has completed its acquisition of Zymergen, a biotech company that designs and produces molecules, microbes and materials. The acquisition is expected to enhance Ginkgo's platform and expand its applications across diverse markets.
Jan 10, 2022 · Zymergen’s initial drug discovery pipeline is focused on high-value oncology targets where precision medicine and Zymergen’s distinctive, complex molecules are expected to provide...
